MedCity News
The mounting behavioral health crisis is our next pandemic
Covid-19 will continue to illuminate the behavioral health crisis, but effective use of digital solutions can drive clinical innovation and expand access to care.
Shares1
“We know we have an intense need. Behavioral health is the next pandemic.” This is how an IT leader at a large health system recently opened a conversation about 2021 goals. Two things struck me: addressing the behavioral health crisis is a rising priority across organizations, and IT leaders are folding behavioral healthcare into their system-wide digital transformations.
Prior to Covid-19, the gap between behavioral health supply and demand was staggering. In 2018, only 43% of adults with mental health needs were able to receive services for all necessary conditions. And it’s only gotten worse. Data from mid-July showed that 53% of adults in the United States reported that the pandemic has negatively impacted their mental health.
Nikki Heider and Jennifer Regan
Nikki Heider is a senior marketing manager at Welltok with more than 15 years of experience in healthcare marketing. Prior to Welltok, Nikki served as marketing/PR manager at Denver Public Health, and as a service line marketing manager at Children’s Hospital Colorado, Boston Children’s Hospital and Dana-Farber Cancer Institute. She has a wealth of communications and public health knowledge which she enjoys applying to marketing solutions in the healthcare industry.
Jennifer Regan is Director of Consumer Engagement, Capital District Physicians’ Health Plan Inc. (CDPHP)Jennifer joined CDPHP in 2019 and leads the team responsible for developing, promoting, refining, and analyzing a wide array
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Prometheus Biosciences is taking a precision medicine approach to developing drugs and diagnostics for inflammatory bowel disease. The IPO cash will fund support its pipeline of IBD drug candidates for specific patient subpopulations.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.